NCT01635686View on ClinicalTrials.gov

Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers

PHASE1UnknownINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Rheumatoid Arthritis
Interventions
DRUG

DWP422 25mg

DRUG

ENBREL 25MG PFS INJ.

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT01635686 - Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter